Chengcheng He

Chengcheng He


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QLQingyuan Li
Qingyuan Li
QLQiuhua Lai
Qiuhua Lai
CHChengcheng He
Chengcheng He
YFYuxin Fang
Yuxin Fang
QYQun Yan
Qun Yan
SLside liu
side liu
Runt-related transcription factor 1 (RUNX1) plays the roles of an oncogene and an anti-oncogene in epithelial tumours, and abnormally elevated RUNX1 has been suggested to contribute to the carcinogenesis of colorectal cancer (CRC). However, the mechanism remains unclear. The expression of RUNX1 in CRC and normal tissues was detected by real-time quantitative PCR and Western blotting. The effect of RUNX1 on CRC migration and invasion was conducted by functional experiments in vitro and in vivo. Chromatin Immunoprecipitation assay verified the direct regulation of RUNX1 on the promoter of the KIT, which leads to the activation of Wnt/β-catenin signaling. RUNX1 expression is upregulated in CRC tissues. Upregulated RUNX1 promotes cell metastasis and epithelial to mesenchymal transition (EMT) of CRC both in vitro and in vivo. Furthermore, RUNX1 can activate Wnt/β-catenin signalling in CRC cells by directly interacting with β-catenin and targeting the promoter and enhancer regions of KIT to promote KIT transcription. These observations demonstrate that RUNX1 upregulation is a common event in CRC specimens and is closely correlated with cancer metastasis and that RUNX1 promotes EMT of CRC cells by activating Wnt/β-catenin signalling. Moreover, RUNX1 is regulated by Wnt/β-catenin. Our findings first demonstrate that RUNX1 promotes CRC metastasis by activating the Wnt/β-catenin signalling pathway and EMT.

1 November 2024 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
QSQiuyu Song
Qiuyu Song
YZYifeng Zheng
Yifeng Zheng
GZGuoqiang Zhong
Guoqiang Zhong
SWShanping Wang
Shanping Wang
CHChengcheng He
Chengcheng He
MLMingsong Li
Mingsong Li
: Colorectal cancer is a common malignant tumor with high morbidity and mortality rates, imposing a huge burden on both patients and the healthcare system. Traditional treatments such as surgery, chemotherapy and radiotherapy have limitations, so finding more effective diagnostic and therapeutic tools is critical to improving the survival and quality of life of colorectal cancer patients. While current tumor targeting research mainly focuses on exploring the function and mechanism of molecular targets and screening for excellent drug targets, it is crucial to test the efficacy and mechanism of tumor cell therapy that targets these molecular targets. Selecting the appropriate drug carrier is a key step in effectively targeting tumor cells. In recent years, nanoparticles have gained significant interest as gene carriers in the field of colorectal cancer diagnosis and treatment due to their low toxicity and high protective properties. Nanoparticles, synthesized from natural or polymeric materials, are NM-sized particles that offer advantages such as low toxicity, slow release, and protection of target genes during delivery. By modifying nanoparticles, they can be targeted towards specific cells for efficient and safe targeting of tumor cells. Numerous studies have demonstrated the safety, efficiency, and specificity of nanoparticles in targeting tumor cells, making them a promising gene carrier for experimental and clinical studies. This paper aims to review the current application of nanoparticles in colorectal cancer diagnosis and treatment to provide insights for targeted therapy for colorectal cancer while also highlighting future prospects for nanoparticle development.

17 August 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
YZYifeng Zheng
Yifeng Zheng
GZGuoqiang Zhong
Guoqiang Zhong
CHChengcheng He
Chengcheng He
MLMingsong Li
Mingsong Li
RNA splicing is the process of forming mature mRNA, which is an essential phase necessary for gene expression and controls many aspects of cell proliferation, survival, and differentiation. Abnormal gene-splicing events are closely related to the development of tumors, and the generation of oncogenic isoform in splicing can promote tumor progression. As a main process of tumor-specific splicing variants, alternative splicing (AS) can promote tumor progression by increasing the production of oncogenic splicing isoforms and/or reducing the production of normal splicing isoforms. This is the focus of current research on the regulation of aberrant tumor splicing. So far, AS has been found to be associated with various aspects of tumor biology, including cell proliferation and invasion, resistance to apoptosis, and sensitivity to different chemotherapeutic drugs. This article will review the abnormal splicing events in colorectal cancer (CRC), especially the tumor-associated splicing variants arising from AS, aiming to offer an insight into CRC-targeted splicing therapy.

15 July 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YZYifeng Zheng
Yifeng Zheng
GZGuoqiang Zhong
Guoqiang Zhong
QSQiuyu Song
Qiuyu Song
HZHaonan Zhang
Haonan Zhang
SWShanping Wang
Shanping Wang
MLMingsong Li
Mingsong Li
Although aberrant splicing events of genes are closely related to the development and progression of colorectal cancer (CRC), the mapping of abnormal splicing events, especially alternative splicing (AS) event types and the underlying effects, remain investigational. In the present study, we analyzed a public RNA-seq database (GSE138202) and identified 14,314 significant AS events in CRC patients compared to healthy individuals. Most of the key genes such as oncogenes involved in the development of CRC have different AS event types. Moreover, the results demonstrate that certain AS events may play a significant role in the functioning of key genes involved in splicing factors and microRNAs. Furthermore, we observed that the oncogene CDK4 in CRC tends to undergo exon 2 skipping AS events, resulting in a stronger tendency for protein expression to form complexes with CCND1, thereby inhibiting the cell cycle and weakening cell proliferation, while enhancing cell migration capability. These findings not only provide new insights into the mechanism of AS in regulating CRC, but also offers a theoretical basis for targeted splicing therapy in CRC.

23 March 2026 in Translational Oncology
Verified
Journal Article
Open access
QCQiusan Chen
Qiusan Chen
QSQiuyu Song
Qiuyu Song
HZHaonan Zhang
Haonan Zhang
ZLZhaoxian Lin
Zhaoxian Lin
YSYulu Shi
Yulu Shi
MLMingsong Li
Mingsong Li
Colorectal cancer (CRC) ranks as the third most common malignancy worldwide. Cyclin dependent kinase inhibitor 2A (CDKN2A) is a key regulatory gene in the recently identified cell death pathway known as cuproptosis. The small nucleolar RNA host gene 7 (SNHG7) is an important and versatile molecule engaged in a variety of tumorigenic processes. Poly(rC)-binding protein 2 (PCBP2) is an RNA-binding protein that enhances RNA stability and is implicated in the progression of various tumors. However, the clinical role of cuproptosis-related SNHG7 in CRC largely remains unclear. We conducted cell culture and subcutaneous tumor formation experiments in nude mice, followed by qPCR, Western blotting, RNA immunoprecipitation, lactate production assays, gel electrophoresis, and immunohistochemistry on the corresponding tissues. Our results demonstrate that SNHG7 interacts with PCBP2 to enhance the expression of CDKN2A, thereby modulating cuproptosis and promoting glycolysis. These findings suggest that SNHG7 represents a promising therapeutic target for CRC.

17 October 2026 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
HZHaonan Zhang
Haonan Zhang
YSYulu Shi
Yulu Shi
QSQiuyu Song
Qiuyu Song
NLNa Li
Na Li
ZLZhaoxian Lin
Zhaoxian Lin
MLMingsong Li
Mingsong Li